DNA Damage Response and Inflammatory Signaling Limit the MLL-ENL-Induced Leukemogenesis In Vivo

Cancer Cell

Volumn 21, Issue 4, 2012, Pages 517-531

  Takacova, Sylvia ^a   Slany, Robert ^b   Bartkova, Jirina ^c   Stranecky, Viktor ^d   Dolezel, Petr ^a   Luzna, Pavla ^a   Bartek, Jiri ^a,c   Divoky, Vladimir ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^d Charles University in Prague and General University Hospital in Prague   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; ATR PROTEIN; CD11B ANTIGEN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CXCL2 CHEMOKINE; ENL PROTEIN; ESTROGEN RECEPTOR; INTERLEUKIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MIXED LINEAGE LEUKEMIA PROTEIN; PROTEIN P21; PROTEIN P53; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER STEM CELL; CELL AGING; CELL IMMORTALIZATION; CELL MATURATION; CELL PROLIFERATION; CELL RENEWAL; CELL TRANSFORMATION; CONTROLLED STUDY; DNA DAMAGE; EMBRYO; GENE EXPRESSION; GENE REARRANGEMENT; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; IN VIVO STUDY; LEUKEMOGENESIS; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENESCENCE; SIGNAL TRANSDUCTION;

MUS;

EID: 84859807068     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2012.01.021     Document Type: Article

References (33)

1. Acosta J.C., O'Loghlen A., Banito A., Guijarro M.V., Augert A., Raguz S., Fumagalli M., Da Costa M., Brown C., Popov N., et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 2008, 133:1006-1018.
2. Bartkova J., Horejsí Z., Koed K., Krämer A., Tort F., Zieger K., Guldberg P., Sehested M., Nesland J.M., Lukas C., et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005, 434:864-870.
3. Bartkova J., Rezaei N., Liontos M., Karakaidos P., Kletsas D., Issaeva N., Vassiliou L.V., Kolettas E., Niforou K., Zoumpourlis V.C., et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006, 444:633-637.
4. Bartek J., Hodny Z., Lukas J. Cytokine loops driving senescence. Nat. Cell Biol. 2008, 10:887-889.
5. Boehrer S., Adès L., Tajeddine N., Hofmann W.K., Kriener S., Bug G., Ottmann O.G., Ruthardt M., Galluzzi L., Fouassier C., et al. Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome. Oncogene 2009, 28:2205-2218.
6. Campisi J., d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat. Rev. Mol. Cell Biol. 2007, 8:729-740.
7. Chen W., Kumar A.R., Hudson W.A., Li Q., Wu B., Staggs R.A., Lund E.A., Sam T.N., Kersey J.H. Malignant transformation initiated by Mll-AF9: gene dosage and critical target cells. Cancer Cell 2008, 13:432-440.
8. Cozzio A., Passegué E., Ayton P.M., Karsunky H., Cleary M.L., Weissman I.L. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev. 2003, 17:3029-3035.
9. Di Micco R., Fumagalli M., Cicalese A., Piccinin S., Gasparini P., Luise C., Schurra C., Garre' M., Nuciforo P.G., Bensimon A., et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006, 444:638-642.
10. Dimri G.P., Lee X., Basile G., Acosta M., Scott G., Roskelley C., Medrano E.E., Linskens M., Rubelj I., Pereira-Smith O., et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. USA 1995, 92:9363-9367.
11. Dobson C.L., Warren A.J., Pannell R., Forster A., Lavenir I., Corral J., Smith A.J.H., Rabbitts T.H. The mll-AF9 gene fusion in mice controls myeloproliferation and specifies acute myeloid leukaemogenesis. EMBO J. 1999, 18:3564-3574.
12. Forsberg E.C., Passegué E., Prohaska S.S., Wagers A.J., Koeva M., Stuart J.M., Weissman I.L. Molecular signatures of quiescent, mobilized and leukemia-initiating hematopoietic stem cells. PLoS ONE 2010, 5:e8785.
13. Gorgoulis V.G., Vassiliou L.V., Karakaidos P., Zacharatos P., Kotsinas A., Liloglou T., Venere M., Ditullio R.A., Kastrinakis N.G., Levy B., et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005, 434:907-913.
14. Halazonetis T.D., Gorgoulis V.G., Bartek J. An oncogene-induced DNA damage model for cancer development. Science 2008, 319:1352-1355.
15. Kastan M.B., Bartek J. Cell-cycle checkpoints and cancer. Nature 2004, 432:316-323.
16. Krivtsov A.V., Twomey D., Feng Z., Stubbs M.C., Wang Y., Faber J., Levine J.E., Wang J., Hahn W.C., Gilliland D.G., et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006, 442:818-822.
17. Krones-Herzig A., Adamson E., Mercola D. Early growth response 1 protein, an upstream gatekeeper of the p53 tumor suppressor, controls replicative senescence. Proc. Natl. Acad. Sci. USA 2003, 100:3233-3238.
18. Littlewood T.D., Hancock D.C., Danielian P.S., Parker M.G., Evan G.I. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res. 1995, 23:1686-1690.
19. Liu S., Shiotani B., Lahiri M., Maréchal A., Tse A., Leung C.C., Glover J.N., Yang X.H., Zou L. ATR autophosphorylation as a molecular switch for checkpoint activation. Mol. Cell 2011, 43:192-202.
20. Lu Y.P., Lou Y.R., Peng Q.Y., Xie J.G., Nghiem P., Conney A.H. Effect of caffeine on the ATR/Chk1 pathway in the epidermis of UVB-irradiated mice. Cancer Res. 2008, 68:2523-2529.
21. Min I.M., Pietramaggiori G., Kim F.S., Passegué E., Stevenson K.E., Wagers A.J. The transcription factor EGR1 controls both the proliferation and localization of hematopoietic stem cells. Cell Stem Cell 2008, 2:380-391.
22. Nam E.A., Zhao R., Glick G.G., Bansbach C.E., Friedman D.B., Cortez D. Thr-1989 phosphorylation is a marker of active ataxia telangiectasia-mutated and Rad3-related (ATR) kinase. J. Biol. Chem. 2011, 286:28707-28714.
23. Rakoff-Nahoum S., Medzhitov R. Toll-like receptors and cancer. Nat. Rev. Cancer 2009, 9:57-63.
24. Ramana C.V., Cheng G.-S., Kumar A., Kwon H.-J., Enelow R.I. Role of alveolar epithelial early growth response-1 (Egr-1) in CD8+ T cell-mediated lung injury. Mol. Immunol. 2009, 47:623-631.
25. Rodier F., Coppé J.-P., Patil C.K., Hoeijmakers W.A.M., Muñoz D.P., Raza S.R., Freund A., Campeau E., Davalos A.R., Campisi J. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat. Cell Biol. 2009, 11:973-979.
26. Santaguida M., Schepers K., King B., Sabnis A.J., Forsberg E.C., Attema J.L., Braun B.S., Passegué E. JunB protects against myeloid malignancies by limiting hematopoietic stem cell proliferation and differentiation without affecting self-renewal. Cancer Cell 2009, 15:341-352.
27. Steidl U., Rosenbauer F., Verhaak R.G., Gu X., Ebralidze A., Otu H.H., Klippel S., Steidl C., Bruns I., Costa D.B., et al. Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells. Nat. Genet. 2006, 38:1269-1277.
28. Yan S.-F., Fujita T., Lu J., Okada K., Shan Zou Y., Mackman N., Pinsky D.J., Stern D.M. Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress. Nat. Med. 2000, 6:1355-1361.
29. Wajapeyee N., Wang S.Z., Serra R.W., Solomon P.D., Nagarajan A., Zhu X., Green M.R. Senescence induction in human fibroblasts and hematopoietic progenitors by leukemogenic fusion proteins. Blood 2010, 115:5057-5060.
30. Wang D., Dubois R.N. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 2010, 29:781-788.
31. Wang J., Iwasaki H., Krivtsov A., Febbo P.G., Thorner A.R., Ernst P., Anastasiadou E., Kutok J.L., Kogan S.C., Zinkel S.S., et al. Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease. EMBO J. 2005, 24:368-381.
32. Zhao Z., Zuber J., Diaz-Flores E., Lintault L., Kogan S.C., Shannon K., Lowe S.W. p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Genes Dev. 2010, 24:1389-1402.
33. Zuber J., Radtke I., Pardee T.S., Zhao Z., Rappaport A.R., Luo W., McCurrach M.E., Yang M.M., Dolan M.E., Kogan S.C., et al. Mouse models of human AML accurately predict chemotherapy response. Genes Dev. 2009, 23:877-889.